There are statements I Second, I would never say that "none of these chemicals have been conclusively linked to adverse health effects," as the article appears to paraphrase me having said. I believe that scientific studies conclusively link all these chemicals, and still more, with harmful health effects in exposed populations. What I recall having said to Lauerman is that it is almost impossible to link, with any confidence, the cancer or other health problem of a given individual with exposure to pesticides. Thus, although a population may experience an increase in cancers or other health problems in the aggregate, the likelihood of a person with a cancer being able to prove to the satisfaction of a court of law that his or her disease was the result of exposure to a chemical is vanishingly small. Correspondence Second, the authors excluded patients with advanced breast cancer because of the significant mortality in this group.
Third, the authors argued that exdusion of women with specific exposures is unlikely to have introduced bias. However, we are not told how many of the original study group were successfully contacted, what proportion had died, and what proportion of those recontacted, and eligible, agreed to participate in the second study. Did these proportions differ between cases and controls?
Fourth, in addition to the possibility of selection bias due to differential recruitment in the second study, the lack of a significant difference between cases and controls may be due to the restriction of the study to early stage cancer. In the study by Kabat et al. (2), among postmenopausal women the ratio of 2-OHE1/16a-OHE1 was strongly and inversely associated with breast cancer. However, this association was driven primarily by a strong association with later stage cancer (stages III and IV).
Finally, in the small sample for which the results were reported, adjustment for breast cancer risk factors (induding age at menarche, age at first pregnancy, parity, family history of breast cancer, and ethnicity) was apparently not carried out. This is critical because the matched-pair design of the original study was not maintained in the current study.
We look forward to the full report, which will hopefully provide more detailed information on these questions. It 
Response
Our pilot study (1) did not confirm Bradlow et al.'s hypothesis of an inverse association between the urinary ratio 2-OHE1l16a-OHE1 and breast cancer risk.
Kabat and Bradlow raise a number of issues that they believe might pose problems in our study. We examine them in the order in which they were raised. Bradlow and Kabat note that we excluded approximately 55-60% of participants in the original study. As we explicitly state in our description ofour pilot study (1), we contacted women who had participated in a previous case-control study at our institution. For the current study, we only contacted women with early stage (< stage II) cancers. This was out of concern that the levels of the urinary metabolites might be altered by the disease in later stage patients and that any association would be the result of the disease rather than the cause of it. We also had a number of exclusion criteria that applied both to cases and to controls. We excluded cases and controls who were current smokers, who were obese, or who had recently used chemotherapy, had anesthesia, or had used other medications that could interfere with estrogen metabolism. We agree that this might limit the generalizability of the findings, but it should not result in selection bias because the criteria were applied equally to both cases and controls. These restrictions were essential because of concern that these factors could influence urinary metabolite levels and thus produce a noncausal association between the ratio of 2-OHEI to 16a-OHE1 and disease.
In our pilot study publication, we provided the data for the first 25 cases and 23 controls we studied. We did not provide the participation rates/exclusion rates in each group at that time since the data collection was ongoing, so the sample in our pilot study should be regarded as a convenience sample. Further information will be provided in the full study, which will be completed shortly.
Kabat et al. (2) provided no information on choice ofcases and controls. In their study, cases were 4 times as likely as controls to currently use alcohol and 3.8 times as likely to have a chronic condition (such as hypertension, arthritis, diabetes, asthma, glaucoma, heart disease ,and allergies); these large differences suggest that their control group may not have been an appropriate comparison group.
Bradlow and Kabat are concerned that lack of adjustment for various breast cancer risk factors would have biased our results toward the null. Although this is possible, their interpretation of their own results makes it appear unlikely. They reported that the 2-OHE1/16a-OHEI ratio "did not show any consistent associations with age, race/ethnicity, age at first birth, parity, body mass index, family history of breast cancer, smoking or alcohol intake" (2) . Bradlow and Kabat give no discussion of why the confounding would be negative. Indeed, positive confounding would appear to be equally, and possibly more, likely. In reality, it should be remembered that most of the breast cancer risk factors are relatively weak and their association with urinary metabolites would need to be rather strong to influence the associations substantively. We will evaluate all these factors as potential confounders in our full study.
Our results are, in fact, in agreement with those reported by Kabat et al. (2) , who also found no association between the ratio of urinary 2-OHE1 to 16a-OHE1 and early stage breast cancer. As they indicate in their letter, the association they found overall was driven primarily by strong associations with later stage cancer in postmenopausal women (the same association was not found for premenopausal women). The strong association Kabat et al. (2) 
